LY3295668 erbumine + endocrine therapy

**LY3295668 erbumine + endocrine therapy** is a combination regimen consisting of LY3295668 erbumine, a highly selective small molecule inhibitor of **Aurora kinase A**, and one or more endocrine therapies commonly used in hormone-driven cancers (e.g., breast cancer). LY3295668 erbumine inhibits Aurora kinase A—an enzyme implicated in cell cycle regulation, tumorigenesis, and stabilization of MYCN/MYC proteins—by binding competitively and selectively at the kinase's ATP-binding site, thereby suppressing cellular proliferation and enhancing cell death in tumor cells. The rationale for combining LY3295668 erbumine with endocrine therapy is to target both cell cycle dysregulation and hormone receptor pathways, particularly in hormone-dependent cancers such as select breast malignancies[3][8][10]. Endocrine therapy typically refers to agents modulating estrogen receptor activity, such as aromatase inhibitors, selective estrogen receptor modulators (SERMs), or selective estrogen receptor degraders (SERDs).

Other names

LY3295668LY-3295668LY 3295668